George Canellos Sandra Strauss Nancy Baxter KIT Mutations in Acute Myeloid Leukemia Confer Higher Relapse Risk Liver Metastasis Resection Not Curative for Colorectal Cancer Patients With Node Negative
George Canellos
Sandra Strauss
Nancy Baxter
KIT Mutations in Acute Myeloid Leukemia Confer Higher Relapse RiskLiver Metastasis Resection Not Curative for Colorectal CancerPatients With Node Negative Breast Cancer: Low Risk After Mastectomy
REFERENCES: J Clin Oncol 34:3904, 3927, 3939GEORGE CANELLOS, Dana-Farber Cancer Institute, BostonIn adult acute myeloid leukemia the detection of KIT mutations was associated with higher relapse risk, according to a study from Columbus, Ohio, reviewed byGeorge Canellos. Dr Canellos also discussed findings from Paris that complete dissection of liver metastasis is not curative for colorectal cancer, and results from Boston that patients with large breast cancers removed by mastectomy may expect low locoregional recurrence rates if they are lymph-node negative, and therefore do not need postmastectomy radiotherapy.
Combination Immunotherapy: Promising For Patients With Refractory or Recurrent Non-Hodgkin’s Lymphoma
REFERENCE: J Clin Oncol 24:3880SANDRA STRAUSS, Royal Free Hospital, LondonCOMMENT: George CanellosA new combination of immunotherapy agents – the anti-CD22 antibody epratuzumab and the anti CD20 rituximab – has shown promise for the treatment of patients whose non-Hodgkin’s lymphoma is recurrent or has become refractory to standard therapy.Sandra Straussof London’s Royal Free Hospital told Peter Goodwin about the findings from her study published in the Journal of Clinical Oncology.
Stage IIIB, IIIC Colon Cancer: Negative Lymph Nodes, Longer Survival
REFERENCE: J Clin Oncol 24:3570NANCY BAXTER, St Michael’s Hospital, TorontoCOMMENT: George CanellosIn Stage III colon cancer having fewer negative lymph nodes leads to shorter survival, according to the findings of a study from St Michael’s Hospital in Toronto. Having more negative nodes is associated with longer survival.Nancy Baxterdiscussed the investigation with Derek Thorne.
Related Episodes
Kerstin Wimmer MD; 2026 EBCC: Polyurethane-Coated Implants Reduce Capsular Contracture Risk after Mastectomy with Radiotherapy for Breast Cancer
Kerstin Wimmer MD, at the 2026 EBCC, discussed the OPBC-09 PRExRT study findings, revealing that polyurethane-coated breast implants significantly reduce capsular contracture risk for breast cancer patients receiving mastectomy with immediate pre-pectoral reconstruction followed by radiotherapy. Thi
Juan Du MD PhD, ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.
Gaorav Gupta MD PhD; SABCS 2025: Pre-Op Radiation Improved T-cell Infiltration in Hormone Receptor-positive, HER2-negative Invasive Breast Cancer; Could Boost Systemic Therapy Responses
At SABCS 2025, Gaorav Gupta MD PhD presented findings from the TBCRC-053 (P-RAD) study. The research showed that pre-operative radiation therapy significantly increased T-cell infiltration in hormone receptor-positive, HER2-negative invasive breast cancer. This novel approach could enhance anti-tumor immunity and boost responses to systemic therapies like immunotherapy and chemotherapy in this common breast cancer subtype.